Caribou Biosciences (CRBU) Enterprise Value (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Enterprise Value data on file, last reported at -$117.6 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 43.58% year-over-year to -$117.6 million in Q1 2026; TTM through Mar 2026 was -$117.6 million, a 43.58% increase from a year earlier, with the FY2025 full-year figure at -$139.3 million, up 33.5% from the prior year.
• Enterprise Value for Q1 2026 stood at -$117.6 million, up from -$139.3 million in the prior quarter.
• Over the last five years, Enterprise Value for CRBU reached as high as -$117.6 million in Q1 2026 and fell as low as -$353.7 million in Q1 2022.
• Historically, Enterprise Value has averaged -$245.9 million across 5 years, with a median of -$247.7 million in 2022.
• Across the five-year window, Enterprise Value slumped 162.44% in 2022 and soared 43.58% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$247.7 million in 2022, then sank by 32.77% to -$328.8 million in 2023, then jumped by 36.28% to -$209.5 million in 2024, then jumped by 33.5% to -$139.3 million in 2025, then gained by 15.58% to -$117.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$117.6 million in Q1 2026, -$139.3 million in Q4 2025, and -$147.3 million in Q3 2025.